Literature DB >> 6428580

Guillain-Barré syndrome and Campylobacter jejuni: a serological study.

J Kaldor, B R Speed.   

Abstract

The association between Campylobacter jejuni infection and Guillain-Barré syndrome was investigated serologically in a retrospective study of 56 patients admitted to this hospital over four years. Evidence of preceding C jejuni infection was found in 21 (38%) of these patients, indicating that C jejuni was the most common single identifiable pathogen precipitating the disease. Among those patients who had presented with preceding diarrhoea the serum antibody response was similar to that in uncomplicated C jejuni enteritis. Patients with serological evidence of preceding C jejuni infection manifested a significantly more severe form of the disease. In cerebrospinal fluid the predominant specific antibody class was IgG, and this was closely related to the serum titres of specific IgG. IgA and IgM specific antibodies were found only in the cerebrospinal fluid of patients with recent C jejuni infection. These findings support the possibility that humoral immune factors are responsible for the neural damage and demyelination seen in Guillain-Barré syndrome.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428580      PMCID: PMC1441765          DOI: 10.1136/bmj.288.6434.1867

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  20 in total

1.  Lymphocyte transformation in the Guillain-Barré syndrome.

Authors:  M Knowles; S Currie; M Saunders; J N Walton; E J Field
Journal:  Lancet       Date:  1969-11-29       Impact factor: 79.321

2.  Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.

Authors:  J Finne; M Leinonen; P H Mäkelä
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

3.  Guillain-Barré syndrome associated with Campylobacter jejuni enteritis.

Authors:  B Speed; J Kaldor; P Cavanagh
Journal:  J Infect       Date:  1984-01       Impact factor: 6.072

4.  Guillain-Barre syndrome associated with Campylobacter infection.

Authors:  K M Rhodes; A E Tattersfield
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-17

5.  The Guillain-Barré syndrome following Campylobacter enteritis with recovery after plasmapheresis.

Authors:  O C Constant; C C Bentley; A M Denman; J R Lehane; H E Larson
Journal:  J Infect       Date:  1983-01       Impact factor: 6.072

6.  Immunoglobulins in the cerebrospinal fluid of patients with Guillain-Barré syndrome.

Authors:  G C Dart; J Kaldor
Journal:  Med J Aust       Date:  1981-10-17       Impact factor: 7.738

7.  Complement-fixing antiperipheral nerve myelin antibodies in patients with inflammatory polyneuritis and with polyneuropathy and paraproteinemia.

Authors:  N Latov; R B Gross; J Kastelman; T Flanagan; S Lamme; D A Alkaitis; M R Olarte; W H Sherman; L Chess; A S Penn
Journal:  Neurology       Date:  1981-12       Impact factor: 9.910

8.  Antibodies to peripheral nerve tissue in sera from patients with acute Guillain-Barré syndrome demonstrated by a mixed haemagglutination technique.

Authors:  C A Vedeler; H Nyland; R Matre
Journal:  J Neuroimmunol       Date:  1982-06       Impact factor: 3.478

9.  Serum antibodies in Campylobacter enteritis.

Authors:  J Kaldor; H Pritchard; A Serpell; W Metcalf
Journal:  J Clin Microbiol       Date:  1983-07       Impact factor: 5.948

10.  Cholera-like enterotoxin produced by Campylobacter jejuni. Characterisation and clinical significance.

Authors:  G M Ruiz-Palacios; J Torres; N I Torres; E Escamilla; B R Ruiz-Palacios; J Tamayo
Journal:  Lancet       Date:  1983-07-30       Impact factor: 79.321

View more
  38 in total

Review 1.  Guillain-Barré syndrome: a century of progress.

Authors:  John A Goodfellow; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2016-11-18       Impact factor: 42.937

2.  Characterization of a bifunctional pyranose-furanose mutase from Campylobacter jejuni 11168.

Authors:  Myles B Poulin; Harald Nothaft; Isabelle Hug; Mario F Feldman; Christine M Szymanski; Todd L Lowary
Journal:  J Biol Chem       Date:  2009-11-03       Impact factor: 5.157

3.  The Miller Fischer syndrome following campylobacter enteritis: a report of two cases.

Authors:  T Roberts; A Shah; J G Graham; I N McQueen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-11       Impact factor: 10.154

Review 4.  Pathophysiology of Campylobacter enteritis.

Authors:  R I Walker; M B Caldwell; E C Lee; P Guerry; T J Trust; G M Ruiz-Palacios
Journal:  Microbiol Rev       Date:  1986-03

5.  Electrophysiological studies in Guillain-Barré syndrome: correlation with antibodies to GM1, GD1B and Campylobacter jejuni.

Authors:  F J Vriesendorp; W J Triggs; R F Mayer; C L Koski
Journal:  J Neurol       Date:  1995-07       Impact factor: 4.849

6.  Characteristics of lipo-oligosaccharide loci of Campylobacter jejuni isolates associated with Guillain-Barré Syndrome from Hebei, China.

Authors:  Hai Jiang; Mao-Jun Zhang; Rui-Chun Liu; Xin-Ying Tian; Yi-Xin Gu; Jian-Zhong Zhang
Journal:  Int J Mol Sci       Date:  2010-03-19       Impact factor: 5.923

Review 7.  Quantifying the association between Campylobacter infection and Guillain-Barré syndrome: a systematic review.

Authors:  Kate O Poropatich; Christa L Fischer Walker; Robert E Black
Journal:  J Health Popul Nutr       Date:  2010-12       Impact factor: 2.000

Review 8.  Guillain-Barré syndrome after varicella-zoster infection. Report of two cases.

Authors:  E A Sanders; A C Peters; J W Gratana; R A Hughes
Journal:  J Neurol       Date:  1987-08       Impact factor: 4.849

9.  Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barré syndrome patients mimic human gangliosides in structure.

Authors:  G O Aspinall; S Fujimoto; A G McDonald; H Pang; L A Kurjanczyk; J L Penner
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  Molecular mimicry and the autoimmune response to the peripheral nerve myelin P0 glycoprotein.

Authors:  M Adelmann; C Linington
Journal:  Neurochem Res       Date:  1992-09       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.